DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening & Drug Repositioning Benchmarks

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021, by APExBIO) is a curated set of 2,320 bioactive compounds, each approved by agencies including the FDA, EMA, HMA, CFDA, and PMDA or listed in pharmacopeias (product source). Compounds are pre-dissolved at 10 mM in DMSO and stable for 12 months at -20°C and up to 24 months at -80°C. The library enables high-throughput screening (HTS), high-content screening (HCS), drug repositioning, and mechanistic target identification (see comparison). Recent studies, such as Dong et al. (2024), demonstrate how such libraries accelerate identification of immune-modulating hits (e.g., nilotinib restoring MHC-I in colorectal cancer cells; DOI). This resource is foundational for modern translational pipelines, supporting robust, machine-readable data generation and cross-study reproducibility.

Biological Rationale

High-throughput screening of approved drugs accelerates discovery by leveraging compounds with known pharmacological and safety profiles (APExBIO). Drug repositioning is predicated on the principle that approved molecules, already characterized for absorption, distribution, metabolism, excretion, and toxicity (ADMET), can be repurposed for new indications, reducing development time and cost. In oncology and immunology, insufficient major histocompatibility complex I (MHC-I) expression is a key mechanism of tumor immune evasion (Dong et al. 2024). Screening for agents that modulate such pathways requires libraries that capture mechanistic diversity, including receptor agonists/antagonists, enzyme inhibitors, and pathway regulators. The DiscoveryProbe™ FDA-approved Drug Library is designed to address these needs, providing a vetted source for systematic screening in translational research.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library is not a single compound but a multi-mechanism resource. Its 2,320 compounds encompass:

• Receptor agonists (e.g., β-adrenergic agonists)
• Receptor antagonists (e.g., angiotensin II receptor blockers)
• Enzyme inhibitors (e.g., doxorubicin as a topoisomerase inhibitor, metformin as a mitochondrial complex I inhibitor)
• Ion channel modulators (e.g., calcium channel blockers)
• Signal pathway regulators (e.g., nilotinib, a BCR-ABL kinase inhibitor shown to activate cGAS-STING-NF-κB and suppress PCSK9 in CRC cells, thus enhancing MHC-I expression; Dong et al. 2024)

Each compound is annotated with its mechanism of action, regulatory status, and clinical indication, supporting data-driven repurposing and mechanistic hypothesis generation. The library’s format (10 mM DMSO solutions) ensures uniform dispensing and compatibility with automated platforms for both HTS and HCS assays, enabling rapid, reproducible screening for phenotypic and target-based endpoints (see advanced use cases – this article details covalent inhibitor discovery, while here we focus on immune modulation and pathway regulation).

Evidence & Benchmarks

• Nilotinib, present in DiscoveryProbe™, upregulates MHC-I in colorectal cancer cells via cGAS-STING-NF-κB activation, resulting in enhanced CD8+ T cell cytotoxicity and increased efficacy of anti-PD-L1 immunotherapy (Dong et al. 2024, DOI).
• Library compounds, supplied as 10 mM DMSO solutions in 96-well or deep well plates, retain ≥95% purity, and are stable for 12 months at -20°C and 24 months at -80°C (see product specification).
• High-throughput screening with this library enables rapid identification of repositioning candidates in cancer, neurodegenerative, and rare disease models, with machine-readable output facilitating benchmarking and reproducibility (internal best-practices article – this article extends those practices to immune checkpoint contexts).
• In HTS pilot studies, hit rates for phenotypic modulation (e.g., pathway induction or cell viability rescue) typically range from 0.1–3% under standard assay conditions (e.g., 24–72h incubation, 37°C, relevant cell model; see curated benchmarks).
• All included compounds have established regulatory approval or pharmacopeial listing, supporting translational relevance and facilitating downstream in vivo and clinical validation (APExBIO).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• High-throughput drug repositioning screens in oncology, neurology, and infectious disease
• Mechanistic interrogation of cell signaling, including immune checkpoint regulation and pathway cross-talk
• Identification of novel pharmacological targets and rapid validation in disease-relevant models
• High-content screening workflows integrating imaging or multi-parametric readouts

However, several boundaries must be noted:

Common Pitfalls or Misconceptions

• Not exhaustive: The library is comprehensive for approved drugs but does not include investigational or preclinical compounds.
• Not suitable for covalent binding-only discovery: While some covalent inhibitors are included, the majority are reversible modulators; for covalent-specific workflows see this dedicated article.
• Not a substitute for target validation: Hits identified require mechanistic follow-up (e.g., RNA-seq, knockdown/rescue) to confirm target engagement and pathway specificity (Dong et al. 2024).
• Compound solubility context: All compounds are supplied in DMSO; precipitation or low aqueous solubility may affect activity in certain cell-based assays. Optimization of final assay DMSO concentration is essential.
• Does not guarantee clinical translation: While regulatory approval supports safety, repositioned indications require separate clinical validation.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is delivered in formats compatible with HTS/HCS robotics (96-well, deep well, or 2D barcoded tubes). Each compound is pre-dissolved at 10 mM in DMSO. Recommended initial screening concentration is 1–10 μM, with final DMSO ≤0.5% v/v in biological assays (product manual). Controls for cell viability (e.g., doxorubicin as a cytotoxic positive control) and vehicle (DMSO) are included. For temperature-sensitive workflows, storage at -20°C (≤12 months) or -80°C (≤24 months) is advised. Shipping is on blue ice for evaluation sizes; larger formats may ship at ambient temperature upon request. Integration with multi-parametric readouts (e.g., imaging, transcriptomics) is supported by the library’s comprehensive annotation and machine-readable data files. For scenario-driven best practices and addressing reproducibility, see this article, which this guide updates with immune pathway case studies.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library by APExBIO sets a high benchmark for high-throughput and high-content drug screening, enabling rapid, reproducible identification of repositioning candidates and mechanistic modulators across multiple disease areas. Its regulatory provenance, compound diversity, and robust annotation facilitate translational workflows and support emerging paradigms in immune modulation, such as the restoration of MHC-I to improve ICI efficacy (Dong et al. 2024). As screening technologies and data integration advance, such libraries will remain central to precision drug discovery and translational research.